PO.ET08.01 · 实验与分子治疗
整合转录组学与CRISPRi筛选鉴定乳腺癌固有放射敏感性的决定因素
Integrative transcriptomic and CRISPRi screening identifies determinants of intrinsic radiosensitivity in breast cancer
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:乳腺癌(BC)仍是女性癌症相关死亡的主要原因之一,放射治疗(RT)是其管理的基石。尽管RT有效,但仍有超过15%的患者在RT后出现局部区域复发,这凸显了明确RT应答和耐药的分子决定因素的迫切需求。我们假设,在固有放射敏感和放射抗性BC模型中,电离辐射后发生的转录组变化将为这一差异应答的介导因素提供机制性见解。为研究这一点,我们对一组涵盖固有放射敏感性谱系的BC细胞系进行了体外RNA测序,以表征放射诱导的转录程序。认识到放射抗性的关键介导因素可能不表现出差异表达,我们以全基因组CRISPR干扰(CRISPRi)筛选来补充这一方法,以鉴定调控放射敏感性的其他功能靶点。这些研究共同旨在阐明RT耐药背后的新型分子通路并为未来的治疗策略提供依据。
方法:将8株BC细胞系以4 Gy RT处理,并在处理后24小时收集RNA用于RNA-seq。使用DESeq2进行差异基因表达分析,随后使用Advaita Bioinformatics的iPathwayGuide进行通路分析。对于CRISPRi实验,将表达dCas9-KRAB的BT-549细胞转染Dolcetto文库,并以3次分割的3 Gy RT处理。在最后一剂放射后7天分离DNA用于测序以确定sgRNA丰度,并使用MAGeCK进行分析。
结果:放射在放射敏感和放射抗性模型中均诱导了显著的转录变化,高度富集的通路包括细胞周期调控、DNA复制和范可尼贫血(Fanconi anemia)通路。CRISPRi筛选鉴定出DNA损伤应答的经典调节因子作为放射敏感性的调控因素,以及一些较少表征的候选者,例如钾通道修饰因子KCNG3和剪接体组分U2AF1,其机制研究目前正在进行中。
结论:电离辐射激活的转录组程序主要涉及DNA损伤应答相关通路的表达变化,这与CRISPRi功能筛选中鉴定的顶级命中一致。重要的是,该筛选还揭示了先前未充分探索的放射增敏机制,包括可变剪接和钾通道信号的扰动。这些发现共同凸显了可能构成固有放射抗性基础的生物学脆弱性,并提名了针对高局部BC复发风险女性进行治疗干预的潜在靶点。
查看英文原文 English abstract
Background: Breast cancer (BC) remains a leading cause of cancer-related mortality among women, and radiation therapy (RT) is a cornerstone of its management. Despite its efficacy, more than 15% of patients experience locoregional recurrence following RT, highlighting a critical need to define the molecular determinants of RT response and resistance. We hypothesized that transcriptomic changes that occur after ionizing radiation in intrinsically radiosensitive and radioresistant BC models would offer mechanistic insight into mediators of this differential response. To investigate this, we performed in vitro RNA-sequencing across a panel of BC cell lines spanning a spectrum of intrinsic radiosensitivity to characterize radiation-induced transcriptional programs. Recognizing that key mediators of radioresistance may not exhibit differential expression, we complemented this approach with a genome-wide CRISPR interference (CRISPRi) screen to identify additional functional targets that modulate radiosensitivity. Together, these studies aim to elucidate novel molecular pathways underlying RT resistance and inform future therapeutic strategies
Methods: Eight BC cell lines were treated with 4 Gy RT and RNA was collected 24 hours after treatment for RNA-seq. Differential gene expression analysis with DESeq2 was performed, followed by pathway analysis with Advaita Bioinformatics' iPathwayGuide. For the CRISPRi experiments, dCas9-KRAB-expressing BT-549 cells were transfected with the Dolcetto library and treated with 3 fractions of 3 Gy RT. DNA was isolated for sequencing to determine sgRNA abundance 7 days after the last dose of radiation and analyzed with MAGeCK.
Results: Radiation induced significant transcriptional changes across both radiosensitive and radioresistant models, with highly enriched pathways including cell cycle regulation, DNA replication, and the Fanconi anemia pathway. The CRISPRi screen identified canonical regulators of the DNA damage response as modulators of radiosensitivity, as well as less-characterized candidates such as the potassium channel modifier KCNG3 and the spliceosome component U2AF1 , with mechanistic studies now underway.
Conclusions: Ionizing radiation activates transcriptomic programs predominantly involving expression changes in DNA damage response-replated pathways, consistent with top hits identified in the CRISPRi functional screen. Importantly, the screen also reveals previously underexplored mechanisms of radiosensitization, including perturbations in alternative splicing and potassium channel signaling. Together, these findings highlight biologic vulnerabilities that may underlie intrinsic radioresistance and nominate potential targets for therapeutic intervention in women at high risk of local BC recurrence.
利益披露 Disclosure
B. N. McBean,
Exact Sciences Employment.
P. S. Rana, None..
R. Abou Zeidane, None..
A. Davis, None..
V. Mercer, None..
S. Lichtman-Mikol, None..
C. Diedrich, None..
K. Wilder-Romans, None..
M. Tao, None..
A. P. Boyle, None..
C. Speers, None.